a Clinical Study.the Effect of Addition of Insoluble Antibacterial Nanoparticles(IABN) in Resin Base Provisional Cement

This study is not yet open for participant recruitment.

Verified by Hadassah Medical Organization, December 2007

First Received: July 16, 2007 Last Updated: February 5, 2008 History of Changes

Sponsored by:	Hadassah Medical Organization
Information provided by:	Hadassah Medical Organization
ClinicalTrials.gov Identifier:	NCT00502606

Purpose

The effect of Antibacterial Nanoparticles, Incorporated in cement, on S.mutans in the margins of provisional restorations is going to be examined clinically by using two kinds of provisional cement 1. cement with out antibacterial nanoparticles. 2.cement with small addition of IABN. after one week in the mouth the crowns are to be removed and examined for the presence and quantity of s. mutans. in vitro tests of the same has shown significant reduction in bacterial population around the provisional cement as compared to the regular cement.

Condition
Oral Rehabilitaiton Caries Periodontitis

Study Type:	Observational
Study Design:	Prospective
Official Title:	Clinical Study :The Effect of Antibacterial Nanoparticles, Incorporated in Provisional Resin Based Cement, on S.Mutans in the Margins of Provisional Restorations

Resource links provided by NLM:

MedlinePlus related topics: Antibiotics

U.S. FDA Resources

Further study details as provided by Hadassah Medical Organization:

Study Start Date:

February 2007

Show Detailed Description

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Patients who need provisional restorations.

Exclusion Criteria:

Patients who got antibacterial therapy in the past 3 months.
Patients using chlorhexidine gluconate.
Pregnant women.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00502606

Contacts

Contact: Michael Perez Davidi, DMD	00 972 3 9244859	perezdavidi@bezeqint.net
Contact: Dana Kesler, Bsc	0097239222674	danakesler@gmail.com

Locations

Israel
Hadassah Medical Organization,
Jerusalem,, Israel

Sponsors and Collaborators

Hadassah Medical Organization

Investigators

Principal Investigator:	Michael Perez Davidi, DMD	Hadassah Medical Organization, Jerusalem, Israel
Study Director:	Nir Sterer, DMD PhD	Hadassah Medical Organization, Jerusalem, Israel
Study Chair:	Ervin Weiss, DMD	Hadassah Medical Organization, Jerusalem, Israel

More Information

Additional Information:

Michael Perez Davidi This link exits the ClinicalTrials.gov site

Publications:

Beyth N, Yudovin-Farber I, Bahir R, Domb AJ, Weiss EI. Antibacterial activity of dental composites containing quaternary ammonium polyethylenimine nanoparticles against Streptococcus mutans. Biomaterials. 2006 Jul;27(21):3995-4002. Epub 2006 Mar 27.

Study ID Numbers:	191061HMO-CTIL
Study First Received:	July 16, 2007
Last Updated:	February 5, 2008
ClinicalTrials.gov Identifier:	NCT00502606 History of Changes
Health Authority:	Israel: Israeli Health Ministry Pharmaceutical Administration

Keywords provided by Hadassah Medical Organization:

provisional restoration
antibacterial nanoparticles
cement
biofilm
bacteria

flora
plaque
dental
prosthesis

Study placed in the following topic categories:

Mouth Diseases
Anti-Infective Agents
Anti-Bacterial Agents

Periodontal Diseases
Periodontitis
Stomatognathic Diseases

Additional relevant MeSH terms:

Mouth Diseases
Anti-Infective Agents
Anti-Bacterial Agents
Periodontal Diseases

Periodontitis
Therapeutic Uses
Stomatognathic Diseases
Pharmacologic Actions

ClinicalTrials.gov processed this record on September 11, 2009